Engineered exosomes: a potential therapeutic strategy for septic cardiomyopathy

Area of Science:

• Biomedical Engineering
• Cardiovascular Research
• Sepsis Pathophysiology

Background:

• Septic cardiomyopathy is a critical complication of sepsis, leading to acute heart failure and high mortality.
• Existing treatments for septic cardiomyopathy are limited, necessitating novel therapeutic approaches.
• Engineered exosomes are emerging as a potential therapeutic modality for various diseases.

Purpose of the Study:

• To explore the potential of engineered exosomes in diagnosing and treating septic cardiomyopathy.
• To review strategies for utilizing engineered exosomes to protect cardiac function during sepsis.
• To highlight innovative aspects of exosome engineering for therapeutic applications.

Main Methods:

• Examine exosome surface modification technologies for targeted delivery.
• Investigate exosomes as a multifunctional platform for drug and therapeutic molecule delivery.
• Consider plant exosome-like nanoparticles as potential drug carriers.

Main Results:

• Engineered exosomes can deliver small molecules, proteins, and drugs effectively.
• Several RNA molecules, proteins, and drugs beneficial for septic cardiomyopathy treatment are identified.
• Exosomes demonstrate potential in both diagnosing and treating septic cardiomyopathy.

Conclusions:

• Engineered exosomes represent a promising biotherapeutic strategy for septic cardiomyopathy.
• Challenges remain, including understanding host cell interactions, biodistribution, metabolism, and long-term safety.
• Further research is crucial to translate engineered exosome therapies into clinical practice.